Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

508 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Beta-blockade enhances anthracycline control of metastasis in triple-negative breast cancer.
Chang A, Botteri E, Gillis RD, Löfling L, Le CP, Ziegler AI, Chung NC, Rowe MC, Fabb SA, Hartley BJ, Nowell CJ, Kurozumi S, Gandini S, Munzone E, Montagna E, Eikelis N, Phillips SE, Honda C, Masuda K, Katayama A, Oyama T, Cole SW, Lambert GW, Walker AK, Sloan EK. Chang A, et al. Among authors: katayama a. Sci Transl Med. 2023 Apr 26;15(693):eadf1147. doi: 10.1126/scitranslmed.adf1147. Epub 2023 Apr 26. Sci Transl Med. 2023. PMID: 37099632
Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling.
Horigome E, Fujieda M, Handa T, Katayama A, Ito M, Ichihara A, Tanaka D, Gombodorj N, Yoshiyama S, Yamane A, Yamada K, Horiguchi J, Shinozuka K, Oyama T, Nishiyama M, Rokudai S. Horigome E, et al. Among authors: katayama a. Oncotarget. 2018 Oct 2;9(77):34554-34566. doi: 10.18632/oncotarget.26177. eCollection 2018 Oct 2. Oncotarget. 2018. PMID: 30349649 Free PMC article.
Carboxypeptidase A4 accumulation is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer.
Handa T, Katayama A, Yokobori T, Yamane A, Fujii T, Obayashi S, Kurozumi S, Kawabata-Iwakawa R, Gombodorj N, Nishiyama M, Asao T, Shirabe K, Kuwano H, Oyama T. Handa T, et al. Among authors: katayama a. Int J Oncol. 2019 Mar;54(3):833-844. doi: 10.3892/ijo.2019.4675. Epub 2019 Jan 4. Int J Oncol. 2019. PMID: 30628666 Free PMC article.
β2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer.
Kurozumi S, Kaira K, Matsumoto H, Hirakata T, Yokobori T, Inoue K, Horiguchi J, Katayama A, Koshi H, Shimizu A, Oyama T, Sloan EK, Kurosumi M, Fujii T, Shirabe K. Kurozumi S, et al. Among authors: katayama a. Breast Cancer Res Treat. 2019 Oct;177(3):603-610. doi: 10.1007/s10549-019-05341-6. Epub 2019 Jul 9. Breast Cancer Res Treat. 2019. PMID: 31290053
Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer.
Katayama A, Miligy IM, Shiino S, Toss MS, Eldib K, Kurozumi S, Quinn CM, Badr N, Murray C, Provenzano E, Callagy G, Martyn C, Millican-Slater R, Purdie C, Purnell D, Pinder SE, Oyama T, Shaaban AM, Ellis I, Lee AHS, Rakha EA. Katayama A, et al. Mod Pathol. 2021 Jul;34(7):1271-1281. doi: 10.1038/s41379-021-00738-5. Epub 2021 Feb 1. Mod Pathol. 2021. PMID: 33526875 Free PMC article.
508 results